Edgar Filing: ZIOPHARM ONCOLOGY INC - Form 8-K

ZIOPHARM ONCOLOGY INC Form 8-K April 16, 2008

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

Date of report (date of earliest event reported): April 16, 2008

ZIOPHARM Oncology, Inc.

(Exact name of registrant as specified in its charter)

<u>Delaware</u> <u>0-32353</u> <u>84-1475642</u>

(State or other jurisdiction of (Commission File Number) (IRS Employer Identification incorporation) No.)

1180 Avenue of the Americas, 19th Floor New York, NY 10036

(Address of principal executive offices) (Zip Code)

(646) 214-0700

(Registrant's telephone number, including area code)

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

- o Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
- o Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
- o Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
- o Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Edgar Filing: ZIOPHARM ONCOLOGY INC - Form 8-K

Item 8	.01. C)ther	Events.
--------	--------	-------	---------

On April 16, 2008, ZIOPHARM Oncology, Inc. issued the press release attached hereto as Exhibit 99.1, which is incorporated herein by reference.

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits.

99.1 Press Release dated April 16, 2008.

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

ZIOPHARM Oncology, Inc.: (Registrant)

Date: April 16, 2008 By: /s/ Richard E. Bagley

Richard E. Bagley

Title: President, Chief Operating Officer and Chief

Financial Officer

Edgar Filing: ZIOPHARM ONCOLOGY INC - Form 8-K

Exhibit Index

Exhibit No. Description

99.1 Press Release dated April 16, 2008.